Endothelin 3 (EDN3) Human shRNA Plasmid Kit (Locus ID 1908)

Specifications

Product Data
Product Name	Endothelin 3 (EDN3) Human shRNA Plasmid Kit (Locus ID 1908)
Locus ID	1908
UniProt ID	P14138
Synonyms	ET-3; ET3; HSCR4; PPET3; WS4B
Vector	pGFP-C-shLenti
Format	Lentiviral plasmids
Kit Components	EDN3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1908). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq	NM_000114, NM_001302455, NM_001302456, NM_207032, NM_207033, NM_207034, NM_207034.1, NM_207034.2, NM_207032.1, NM_207032.2, NM_000114.1, NM_000114.2, NM_207033.1, NM_207033.2, NM_001302456.1, NM_001302455.1, BC008876, BC008876.2, BC053866, BC053866.1, NM_207032.3, NM_001302456.2, NM_001302455.2, NM_207034.3, NM_207033.3
Summary	The protein encoded by this gene is a member of the endothelin family. Endothelins are endothelium-derived vasoactive peptides involved in a variety of biological functions. The active form of this protein is a 21 amino acid peptide processed from the precursor protein. The active peptide is a ligand for endothelin receptor type B (EDNRB). The interaction of this endothelin with EDNRB is essential for development of neural crest-derived cell lineages, such as melanocytes and enteric neurons. Mutations in this gene and EDNRB have been associated with Hirschsprung disease (HSCR) and Waardenburg syndrome (WS), which are congenital disorders involving neural crest-derived cells. Altered expression of this gene is implicated in tumorigenesis. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Oct 2014]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.